Disease · MONDO_0001577

respiratory syncytial virus infectious disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. respiratory syncytial virus infectious disease. Diseases, record MONDO_0001577. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001577

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: respiratory syncytial virus infectious disease; Open Targets
Open Targets ID: MONDO_0001577; Open Targets
Other names: Human respiratory syncytial virus infection, RSV infection, respiratory syncytial virus infection; Open Targets
Disease Ontology: DOID:1273; Disease Ontology
MeSH: D018357; MeSH
NCI Thesaurus: C3354; NCI Thesaurus
Highest stage of its drugs: Approval, for 5 of its 35 drugs, from EMA Human Drugs, FDA and TTD; Open Targets

Drugs35

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
NIRSEVIMAB	CHEMBL4297575	Antibody	Approval	FDA	4	1	1	Drugs and targets
RESPIRATORY SYNCYTIAL VIRUS PRE-FUSION GLYCOPROTEIN F	CHEMBL6068489	Vaccine component	Approval	FDA	2	1	0	Drugs and targets
PALIVIZUMAB	CHEMBL1201586	Antibody	Approval	EMA Human Drugs and TTD	2	0	0	Drugs and targets
QS-21	CHEMBL4297817		Approval	EMA Human Drugs	1	0	0	Drugs and targets
RESPIRATORY SYNCYTIAL VIRUS PRE-FUSION GLYCOPROTEIN F MRNA	CHEMBL6068496	Vaccine component	Approval	FDA	1	0	0	Drugs and targets
RILEMATOVIR	CHEMBL4437054	Small molecule	Phase 3	ClinicalTrials.gov	10	9	9	Drugs and targets
ZIRESOVIR	CHEMBL4468815	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
MOTAVIZUMAB	CHEMBL1743042	Antibody	Phase 3	TTD	3	2	2	Drugs and targets
AZITHROMYCIN	CHEMBL529	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
SUPTAVUMAB	CHEMBL3707327	Antibody	Phase 3	TTD	1	0	0	Drugs and targets

1 to 10 of 35

See all 35 drugs

Targets35

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA1A	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/146	Drugs and targets
ADRA2A	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/152	Drugs and targets
ADRB1	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/154	Drugs and targets
ADRB3	Adrenergic receptor	1	Adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/155	Drugs and targets
CCR2	C-C chemokine receptor type 2	1	C-C chemokine receptor type 2 inhibitor	Unknown	https://conductscience.org/library/genes/729230	Drugs and targets

1 to 10 of 35

See all 35 targets

Trials61

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03656510	Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection	Phase 2	246	2023-09-21	Respiratory Syncytial Virus Infections	RILEMATOVIR	Its record names the disease	ClinicalTrials.gov
NCT02135614	Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection	Phase 2	189	2018-05-11	Respiratory Syncytial Virus Infection	PRESATOVIR	Its record names the disease	ClinicalTrials.gov
NCT02254408	Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract	Phase 2	189	2018-08-06	Respiratory Syncytial Virus	PRESATOVIR	Its record names the disease	ClinicalTrials.gov
NCT02979431	Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection	Phase 2	180	2019-10-18	Respiratory Syncytial Virus Lower Respiratory Tract Infection	ALX-0171	Open Targets' reading of its record	ClinicalTrials.gov
NCT03691623	A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model	Phase 2	179	2022-05-03	RSV Infection	ZELICAPAVIR	Its record names the disease	ClinicalTrials.gov
NCT00421304	A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness	Not applicable	118	2021-08-27	RSV Illness in ≤12 Months of Participants	MOTAVIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT05559905	Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)	Phase 2	116	2024-05-20	Respiratory Syncytial Virus	MOLNUPIRAVIR	Its record names the disease	ClinicalTrials.gov
NCT04816721	A Study to Evaluate EDP 938 Regimens in Children With RSV	Phase 2	99	2025-07-08	Respiratory Syncytial Virus (RSV)	ZELICAPAVIR	Its record names the disease	ClinicalTrials.gov
NCT04196101	A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects	Phase 2	82	2023-10-30	Respiratory Syncytial Virus	ZELICAPAVIR	Its record names the disease	ClinicalTrials.gov
NCT03379675	A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus	Phase 2	72	2022-06-28	Respiratory Syncytial Virus Infections	RILEMATOVIR	Its record names the disease	ClinicalTrials.gov

1 to 10 of 61

See all 61 trials

Comparisons in its trials39

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Presatovir vs Placebo: deaths from any cause	2 of 92	0 of 94	186	NCT02135614	Trial comparisons
Presatovir vs Placebo: serious adverse events	8 of 92	13 of 94	186	NCT02135614	Trial comparisons
Presatovir vs Placebo: deaths from any cause	2 of 95	4 of 90	185	NCT02254408	Trial comparisons
Presatovir vs Placebo: serious adverse events	18 of 95	23 of 90	185	NCT02254408	Trial comparisons
Combined EDP-938 vs Combined Placebo: Pooled Population: Number of Participants Who Experienced a TEAE	28 of 70	13 of 26	96	NCT04816721	Trial comparisons
EDP-938 vs Placebo: Number of Participants With Adverse Events	11 of 40	11 of 41	81	NCT04196101	Trial comparisons
EDP-938 vs Placebo: deaths from any cause	0 of 40	0 of 41	81	NCT04196101	Trial comparisons
EDP-938 vs Placebo: serious adverse events	0 of 40	0 of 41	81	NCT04196101	Trial comparisons
Presatovir vs Placebo: deaths from any cause	0 of 40	0 of 20	60	NCT02534350	Trial comparisons
Presatovir vs Placebo: serious adverse events	2 of 40	4 of 20	60	NCT02534350	Trial comparisons

1 to 10 of 39

See all 39 comparisons in its trials

Papers from its trials23

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40175624	RESULT	1	PubMed
37502622	RESULT	1	PubMed
41673909	DERIVED	1	PubMed
40246359	DERIVED	1	PubMed
39441691	DERIVED	1	PubMed
39321361	DERIVED	1	PubMed
38649595	DERIVED	1	PubMed
37467213	DERIVED	2	PubMed
37422079	DERIVED	1	PubMed
37323051	DERIVED	1	PubMed

1 to 10 of 23

See all 23 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001577

GET https://conductscience.org/api/diseases/v1/MONDO_0001577/drugs?page=2

API reference For AI assistants